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SUMMARY
Leukemia stem cells (LSCs) have the capacity to self-renew and propagate disease upon serial 
transplantation in animal models, and elimination of this cell population is required for curative 
therapies. Here, we describe a series of pooled, in vivo RNA interference (RNAi) screens to 
identify essential transcription factors (TFs) in a murine model of acute myeloid leukemia (AML) 
with genetically- and phenotypically-defined LSCs. These screens reveal the heterodimeric, 
circadian rhythm TFs Clock and Bmal1 as genes required for the growth of AML cells in vitro and 
in vivo. Disruption of canonical circadian pathway components produces anti-leukemic effects, 
including impaired proliferation, enhanced myeloid differentiation, and depletion of LSCs. We 
*Correspondence: Benjamin L. Ebert, CONTACT INFORMATION: bebert@partners.org, Address: 1 Blackfan Circle, Karp Building 
(CHRB 05.125), Boston, MA, 02115, Phone: 617-355-9060. 
AUTHOR CONTRIBUTIONS
R.V.P., O.R.R., F.A., A.R., and B.L.E. designed and supervised the research. R.V.P., M.S.K., C.G.D., R.K.S., P.G.M., M.M., Z.T., H.T., 
D.H., M.J., M.C.C., and H.L. performed the research. A.T. provided experimental assistance for the continuous bioluminescence 
studies. R.V.P., M.S.K., C.G.D., R.K.S., M.M., G.S.C., F.A., and B.L.E. analyzed the data. R.V.P. and B.L.E. wrote the manuscript.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Cell. Author manuscript; available in PMC 2017 April 07.
Published in final edited form as:
Cell. 2016 April 7; 165(2): 303–316. doi:10.1016/j.cell.2016.03.015.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
find that both normal and malignant hematopoietic cells harbor an intact clock with robust 
circadian oscillations, and genetic knockout models reveal a leukemia-specific dependence on the 
pathway. Our findings establish a role for the core circadian clock genes in AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor 
cells (HSPCs) characterized by enhanced proliferation and impaired differentiation. 
Recurrent mutations in transcription factors (TFs) and epigenetic regulators identified in 
AML (Dohner et al., 2015; Ley TJ, 2013) suggest that aberrant transcriptional circuits are a 
common feature of leukemogenesis. Collectively, these circuits drive oncogenic gene 
expression programs that inhibit differentiation and activate self-renewal, generating 
leukemia stem cells (LSCs) responsible for the initiation and propagation of disease (Chao et 
al., 2008; Reya et al., 2001; Somervaille and Cleary, 2006).
In leukemias with rearrangements of the Mixed Lineage Leukemia (MLL) gene, activation 
of a self-renewal circuit involving the Hox gene cluster is a key aspect in the transformation 
of committed myeloid progenitor cells (Krivtsov et al., 2009). Studies have identified 
multiple transcription factor dependencies within this circuitry, including HoxA9, Meis1, β-
Catenin, Myc, and Myb, demonstrating that re-wired transcriptional circuits in LSCs may be 
targeted by blocking the activity of single TFs (Faber et al., 2009; Wang et al., 2010; Wong 
et al., 2007; Zuber et al., 2011a). Although both LSCs and normal hematopoietic stem cells 
(HSCs) share the hallmark feature of self-renewal, differences in their transcriptional wiring 
and the degree of functional redundancy within their stemness circuits may offer selective 
therapeutic opportunities (Huntly and Gilliland, 2005; Novershtern et al., 2011).
Recent studies demonstrate that leukemia-specific targets may be identified using short-
hairpin RNA (shRNA) screens to interrogate multiple genes in primary AML cells in vivo 
(Jaras et al., 2014; Miller et al., 2013; Zuber et al., 2011b). These screens employ disease 
models that reflect the phenotypic and functional cellular heterogeneity observed in human 
AML (Lapidot et al., 1994) and aim to study leukemia cells in the context of the niche (Lane 
et al., 2009; Schepers et al., 2015). In vivo screening using primary cell models enables the 
identification of both cell autonomous and cell non-autonomous mechanisms relevant to 
disease biology. We therefore used pooled, in vivo shRNA screening to identify transcription 
factor dependencies in leukemia stem cells.
RESULTS
Pooled In Vivo RNA Interference Screening in LSCs
To identify essential TFs in leukemia and to highlight transcriptional mechanisms of self-
renewal in LSCs, we performed an in vivo RNA interference (RNAi) screen using a serial 
transplantation model of MLL-AF9-driven, myelomonocytic AML derived from dsRed+ 
mice (Figure S1A). LSCs in this model are aggressive, immunophenotypically-defined, and 
may be enriched by prospectively sorting dsRed-labeled cells with high expression of the c-
Kit cell surface marker (Hartwell et al., 2013) (Figure S1B). The short-latency, high 
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penetrance quaternary transplant leukemias are highly enriched for LSCs and are suitable for 
in vivo screening (Miller et al., 2013).
Given the limited number of genes that can be effectively examined in such an in vivo 
screen, we first identified candidate TFs on the basis of gene expression (Bullinger et al., 
2004; Chen et al., 2008; Krivtsov et al., 2009; Metzeler et al., 2008; Novershtern et al., 
2011; Somervaille et al., 2009; Valk et al., 2004; Wang et al., 2010). We selected DNA-
binding proteins that have higher expression in stem cells (LSCs or HSCs) compared to 
myeloid progenitor cells and are co-expressed with the canonical LSC regulators HoxA9 and 
Meis1. The top 152 genes, based on this analysis, were selected for the screen (Table S1A).
To test the functional importance of these candidate genes, we generated a custom pool of 
770 lentiviral shRNAs (approximately 5 shRNAs per gene) and 7 control shRNAs that lack 
complementarity with any known murine genes. Freshly sorted quaternary transplant 
leukemia cells were transduced with 6 subpools of lentiviral shRNAs. An aliquot of these 
cells was banked 24 hours later, and the remainder was transplanted into sublethally 
irradiated mice (5 replicate mice per subpool). Two weeks after transplantation, dsRed+ 
leukemia cells were banked from the bone marrow of moribund recipient mice (Figure S1C). 
Genomic DNA was harvested from both banks of cells and shRNAs were PCR amplified 
and sequenced on the Illumina platform (Moffat et al., 2006).
We compared the quantitative representation of shRNAs in the input and leukemic bone 
marrow samples, and observed strong concordance between biological replicates (Figures 
1A and S1D). We identified 35 transcriptional regulators targeted by at least 3 shRNAs 
depleted greater than 20-fold (Table S1B), indicating that these genes are essential for AML 
cells in vivo. Top hits from the screen are established regulators of LSC function, including 
HoxA9, Meis1, β-Catenin, Pbx1, and Myc (Figure 1B). Other genes that scored are 
implicated in myeloid specification (PU.1), Myc activity (Mlxip), PML bodies (Pml, Mzf1, 
Trim27, Rere), Mef2c signaling (Mef2c, Foxj3), and the circadian rhythm (Clock and 
Bmal1). For key hits, we validated that top scoring shRNAs effectively decrease expression 
of their target gene (Figure S1E).
Clock and Bmal1 are Required for Leukemia Cell Growth
Two hits from our in vivo screen were Clock and Bmal1, encoding bHLH domain-
containing TFs that regulate transcription as a heterodimer (Huang et al., 2012). Multiple 
shRNAs targeting Clock or Bmal1 were depleted greater than 20-fold in vivo, with several 
shRNAs depleted up to 1000-fold (Figure 1B). Clock and Bmal1 are core components of an 
autoregulatory loop that drives robust oscillations in gene expression to regulate circadian 
physiology (Partch et al., 2014; Wager-Smith and Kay, 2000). In the hematopoietic system, 
the circadian clock regulates HSC egress from the bone marrow microenvironment 
(Mendez-Ferrer et al., 2008), hematopoietic engraftment (D’Hondt et al., 2004; Rolls et al., 
2015), and bone marrow mitotic activity (Clark and Korst, 1969; Smaaland et al., 1991). 
Cell autonomous and cell non-autonomous functions of the circadian rhythm in leukemia 
have not been rigorously established.
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We validated a role for Clock and Bmal1 in leukemia in vivo with shRNAs co-expressed 
with GFP from single lentiviral vectors. We transduced murine MLL-AF9 leukemia cells 
with individual shRNAs, transplanted the cells into sublethally irradiated recipient mice, and 
compared the percentage of GFP+ leukemia cells before transplant and after 2 weeks in vivo. 
GFP+ cells expressing Clock or Bmal1 shRNAs were strongly depleted in vivo, while cells 
expressing the luciferase (Luc) control shRNA were stable over time (Figure 1C). To 
evaluate whether this effect is independent of the bone marrow microenvironment or cell 
engraftment, we performed an equivalent experiment in vitro with cytokine supplementation 
(IL3, IL6, and SCF). Similar to the phenotype in vivo, GFP+ cells were depleted over 12 
days in culture following transduction with Clock or Bmal1 shRNAs but not with the Luc 
control (Figure 1D).
To account for possible off-target effects of the shRNAs, we performed a cDNA rescue 
experiment. We generated a retroviral vector that co-expresses GFP and a mutant Bmal1 
cDNA with silent point mutations in the shRNA binding sites. We sequentially transduced 
murine leukemia cells with the rescue vector and Bmal1 shRNAs, followed by puromycin 
selection of shRNA-expressing cells. In this experiment, an increase in the percentage of 
GFP+ cells reflects selection for the shRNA-resistant Bmal1 cDNA and confirms on-target 
effects. Indeed, we observed a significant increase in the GFP+ fraction in vitro for two 
Bmal1 shRNAs (A1 and A6) normalized to the Luc control (Figure 1E).
As an added confirmation of specificity, we used CRISPR-Cas9-based genome editing to 
introduce loss-of-function mutations in the Bmal1 gene in primary murine leukemia cells. 
We transduced quaternary transplant MLL-AF9 cells with lentiviral SFFV-driven Cas9 
followed by puromycin selection of cells with stable Cas9 expression (Heckl et al., 2014). 
Leukemia cells were then transduced with a separate lentiviral vector that co-expresses 
RFP657 and a single guide RNA (sgRNA) targeting luciferase, Bmal1, or HoxA9 as a 
positive control. Consistent with the shRNA results, a sgRNA targeting Bmal1 was 
progressively depleted (Figures 1F–G and S1F).
These data demonstrate that Bmal1 and its heterodimeric partner Clock are functionally 
required for LSCs. Accordingly, we found that Bmal1 expression is induced by MLL-AF9 
(Figure S1G) and is correlated with c-Kit, a marker of LSCs in our serial transplantation 
model of AML (Figures 2A and S2A–B; Table S2).
Circadian Disruption Induces Myeloid Differentiation and Impaired Cell Cycle Progression
We next examined the consequences of acute disruption of the circadian rhythm in AML 
using a small molecule. SR9011 is a potent and specific agonist of the nuclear hormone 
receptors RevErb α and Rev-Erb β, which inhibit Bmal1 transcription via a feedback loop 
(Burris et al., 2013; Solt et al., 2012). Treatment of quaternary transplant MLL-AF9 cells 
with SR9011 for 3 days in vitro resulted in a dose-dependent reduction in cell viability 
(EC50 = 1.8 μM) (Figure 2B). In agreement with known roles of Rev-Erb α and Rev-Erb β 
within the circadian pathway, short duration treatment of leukemia cells with the drug 
resulted in decreased expression of Bmal1 and its target gene Per2 (Figure 2C). In addition, 
we observed dose-dependent suppression of key regulators LSC self-renewal (HoxA9, 
Puram et al. Page 4
Cell. Author manuscript; available in PMC 2017 April 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Meis1, Ctnnb1), indicating that the circadian rhythm circuitry influences functions related to 
stemness (Figure 2D).
Consistent with these observations, we found that Clock or Bmal1 shRNAs in leukemia cells 
induce morphologic changes of monocytic differentiation, including decreased nuclear to 
cytoplasmic ratio and enhanced granularity (Figure 2E). Using flow cytometry, we observed 
reduced cell surface expression of stem cell marker, c-Kit, and increased expression of 
myeloid differentiation markers, CD11b and Gr1 (Figures 2F–G and S2C). Additionally, 
leukemia differentiation following circadian gene knockdown is associated with a reduction 
in the percentage of actively dividing cells (S/G2/M) and an increase in the fraction of cells 
in G0/G1 (Figures 2H and S2D).
Murine Leukemia Cells Harbor a Functional Circadian Clock
Our finding that AML cells are dependent on Clock and Bmal1 expression implies that 
leukemia cells, and perhaps their normal hematopoietic counterparts, harbor an intact 
circadian clock that regulates rhythmic gene expression. To test this possibility in primary 
murine leukemia cells, we used reporter mice with an in-frame knock-in of luciferase at the 
3′ end of the Per2 gene (Yoo et al., 2004). We generated primary MLL-AF9 leukemias in the 
Per2::Luc genetic background, transplanted these leukemias into wild type (WT) recipients 
entrained to a 12 hour light - 12 hour dark (LD12:12) schedule, and followed the mice for 4 
to 6 weeks for the development of disease (Figures S2E–F). Continuous bioluminescence 
recordings of leukemic spleen explants from moribund mice revealed oscillations with a 
period of approximately 24 hours (Figure 3A). Thus, murine leukemia cells have the 
capacity for circadian-dependent gene expression independent of the suprachiasmatic 
nucleus (SCN), the dominant circadian pacemaker in the central nervous system. 
Additionally, continuous bioluminescence measurements of purified Per2::Luc MLL-AF9 
bone marrow cells suspended in liquid culture with cytokines confirmed that these rhythms 
are not dependent on an intact stromal microenvironment (Figure S2G).
Canonical Circadian Machinery Operates in Human AML Cells
We next examined whether the circadian circuitry is intact in human AML, as it is in murine 
leukemia. We found that MLL-WT (SKM-1) and MLL-rearranged (THP-1) leukemia cell 
lines are highly sensitive to CLOCK and BMAL1 knockdown using multiple shRNAs 
(Figures 3B and S2H–I). In THP-1 cells, reciprocal co-immunoprecipitation assays 
demonstrated a physical association between CLOCK and BMAL1, as would be expected 
for cells with an intact circadian mechanism (Figure 3C).
To define a set of CLOCK/BMAL1 targets in human AML, we performed chromatin 
immunoprecipitation sequencing (ChIP-Seq) for both TFs. We called peaks individually for 
CLOCK (269 peaks) and BMAL1 (9584 peaks) in THP-1 cells and defined a high-
confidence set of 140 regions associated with 229 genes bound by both factors (Figure S2J; 
Table S3A). Pathway analysis revealed that CLOCK/BMAL1 targets are significantly 
enriched for genes involved in the circadian rhythm (“Circadian Rhythm – Mammal”; 
MSigDB; Hyper FDR 2.09E-8), including BHLHE40/41, CRY1/2, NR1D1, PER1/2, and 
DBP (Figure 3D; Table S3B). Gene ontology (GO) analysis demonstrated that high-
Puram et al. Page 5
Cell. Author manuscript; available in PMC 2017 April 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
confidence loci are involved in diverse cellular processes, including metabolism, 
differentiation, immune function, cell cycle regulation, and proliferation, as reported in other 
tissue types (Miller et al., 2007; Richards and Gumz, 2012) (Figure 3E). In addition, we 
found CLOCK/BMAL1 binding to Wnt/β-Catenin pathway genes (WNT11, FZD3, WISP1, 
CSNK2A3) and several genes associated with cancer (HRAS, CEBPA, ZEB1, EGLN2). E-
Box sites are among the most enriched motifs in the high-confidence binding regions, 
consistent with the known specificity of these TFs (Weirauch et al., 2014) (Figure 3F; Table 
S3C).
Identification of Additional Circadian Regulators in Leukemia Cells
Given evidence for binding of CLOCK/BMAL1 to multiple conserved circadian genes in 
human AML cells, we hypothesized that additional components of the pathway are required 
for LSC function. We evaluated this possibility by performing an in vivo minipool screen in 
murine MLL-AF9 cells with shRNAs targeting 22 genes in the canonical circadian pathway, 
including Clock and Bmal1 and several key regulators. This screen confirmed a role for 
Clock/Bmal1 and highlighted additional pathway genes (Per1/3, Cry1, and Csnk1e/2a1/2b), 
raising the possibility that both positive and negative elements of the circadian 
transcriptional-translational feedback loop impact LSC function (Figure 3G; Table S4). 
Interestingly, a subset of the hits from this screen (Per1, Cry1) are directly bound by the 
Clock/Bmal1 complex and may represent essential mediators of Clock and Bmal1 activity in 
AML (Figure 3G).
Role of the Circadian Rhythm Pathway in Normal Hematopoiesis
Having established a functional requirement for Clock and Bmal1 in leukemia, we next 
examined their roles in normal hematopoiesis. Continuous bioluminescence studies with 
spleen explants from healthy Per2::Luc transgenic mice entrained to LD12:12 revealed 
persistent oscillations with a period of approximately 24 hours (Figure 4A). The circadian 
activity observed in these mice could reflect either rhythms in hematopoietic cells or 
oscillations in extra-hematopoietic cells within the spleen. We thus performed bone marrow 
transplantation experiments to study the rhythm specifically in HSPCs and their progeny. We 
harvested bone marrow from healthy Per2::Luc mice and transplanted c-Kit enriched cells to 
lethally irradiated WT mice. Continuous bioluminescence recordings of spleen explants 
from these mice revealed robust rhythms with a period of approximately 24 hours (Figure 
4B).
The presence of an intact clock in normal hematopoietic cells, in conjunction with evidence 
that Clock and Bmal1 are more highly expressed in HSPCs compared to differentiated cells 
(Figures 4C–D), raises the possibility that the circadian rhythm impacts HSC function. We 
sought to determine the effect of circadian gene disruption on normal hematopoiesis using 
germline Bmal1 knockout mice that lack a functional circadian pacemaker in all tissues 
(Bunger et al., 2000). These mice display premature death, infertility, organ shrinkage, age-
related pathologies such as cataracts, and increased reactive oxygen species, indicating that 
Bmal1 may be required for normal tissue stem cell homeostasis (Alvarez et al., 2008; 
Kondratov et al., 2006; Kondratov et al., 2009).
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We used multi-parameter flow cytometry (Figures S3A–D) to assess Bmal1−/− mice (Figure 
S4A) for defects in hematopoietic function and/or differentiation. We first gated lineage−, 
Scal+, c-Kit+ (LSK) cells, with further separation based on the SLAM markers CD48 and 
CD150, to examine the stem cell compartment in these mice (Kiel et al., 2005). We 
identified a significant reduction in the percentage of both LSK cells and long-term HSCs 
(LT-HSCs) in Bmal1−/− animals compared to age-matched Bmal1+/− controls (Figures 4E–
G; Table S5). However, we did not observe a corresponding reduction in the frequency of 
mature myeloid or lymphoid cells in the bone marrow or spleens of Bmal1−/− mice, possibly 
due to compensatory mechanisms (Figure 4H and S4B). Similarly, an evaluation of myeloid 
progenitor cells did not reveal significant abnormalities in common myeloid progenitor 
(CMP), granulocyte monocyte progenitor (GMP), or megakaryocyte erythroid progenitor 
(MEP) populations (Figure 4I; Table S5).
Because germline Bmal1−/− mice have disrupted central pacemaker function, globally 
altered molecular and behavioral rhythms, and diverse tissue phenotypes, the stem cell 
finding in these mice may be related to either cell autonomous or cell non-autonomous 
effects. Consequently, we sought to highlight cell intrinsic effects by inactivating Bmal1 in 
adult hematopoiesis with preservation of the circadian rhythm in the SCN and non-
hematopoietic peripheral tissues.
We examined the role of Bmal1 in hematopoietic cells in competitive repopulation assays 
using conditional knockout mice in which LoxP sites flank the critical bHLH domain of 
Bmal1 (Storch et al., 2007). We mixed WT cells expressing CD45.1 with equal numbers of 
either Bmal1f/f; MxCre+ cells or Bmal1+/+; MxCre+ cells marked by CD45.2, and 
transplanted the mix to lethally irradiated CD45.1+ recipient mice. Following engraftment, 
we treated the full cohort of mice with polyinosinic-polycytidylic acid (poly(I:C)), inducing 
Cre expression and Bmal1 inactivation in Bmal1f/f; MxCre+ hematopoietic cells. We serially 
measured the peripheral blood CD45.2 chimerism by flow cytometry over 24 weeks in vivo, 
and did not identify significant abnormalities in repopulating ability or multi-lineage 
differentiation of Bmal1 knockout HSPCs compared to control HSPCs (Figures 4J and S4C–
F). Importantly, we did not detect differences in the frequencies of CD45.2-derived LSK 
cells or LT-HSCs between the 2 groups, and no significant hematopoietic phenotypes were 
observed with secondary transplantation (Figures 4K–L and S4G–H).
Consistent with these data, we found that normal murine LSK cells are resistant to Bmal1 
knockdown with multiple shRNAs (Figure S4I). In addition, analyses of non-competitive 
Bmalf/f; MxCre+ mice and germline Per2 mutant (Per2m/m) mice (Zheng et al., 1999) did not 
reveal gross hematopoietic deficits (Figures S5A–I). Collectively, these studies demonstrate 
that loss of Bmal1 (or Per2) in adult hematopoiesis is well tolerated.
Genetic Knockout Confirms a Leukemia-Specific Dependence on Bmal1
We used the Bmal1 conditional knockout model to evaluate the phenotypic consequences of 
complete loss of Bmal1 activity on leukemia maintenance. We generated murine MLL-AF9 
leukemias in the Bmal1f/f background and retrovirally transduced the cells with PIG-Cre, 
resulting in efficient excision (Figure 5A). Consistent with our shRNA and CRISPR-Cas9 
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results, homozygous Bmal1 loss resulted in an in vitro leukemia growth defect compared to 
the Bmal1+/+ control (Figure 5A).
We next evaluated the effect of Bmal1 inactivation on the initiation and propagation of 
MLL-AF9 leukemia. We treated Bmal1f/f; MxCre+ or Bmal1+/+; MxCre+ animals with 
poly(I:C), harvested bone marrow from these mice, and confirmed excision (Figure S5J). C-
Kit enriched cells from both groups of mice were retrovirally transduced with MIG-MLL-
AF9 and transplanted into lethally irradiated WT recipients. Although we did not observe 
differences in leukemia latency or overall survival between the primary transplant groups, 
secondary recipient mice receiving Bmal1−/− MLL-AF9 cells lived significantly longer than 
mice receiving Bmal1+/+ MLL-AF9 cells (Figure 5B). Thus, Bmal1 is required for disease 
propagation.
Given these findings, in conjunction with the HSC knockout studies, we reasoned that AML 
cells may be differentially sensitive to circadian disruption with the Rev-Erb α/β agonist 
SR9011. To test this hypothesis, we measured the viability of quaternary transplant MLL-
AF9 cells and normal murine LSK cells following treatment with SR9011 for 3 days in 
vitro. We found that murine leukemia cells are more sensitive than HSPCs to various 
concentrations of drug (Figure 5C). Similarly, SR9011 had greater activity in human AML 
cell lines (NOMO-1 and MOLM-13) compared to CD34+ cord blood cells purified from 
healthy donors (Figure 5D). These data indicate that myeloid leukemia cells, in contrast to 
normal hematopoietic cells, are highly sensitive to perturbation of the core circadian rhythm 
genes.
Finally, we interrogated genomic data from The Cancer Genome Atlas (TCGA) to determine 
if central circadian components (Clock, Bmal1, and Per2) are somatically disrupted in 
human AML (Ley TJ, 2013). In the 191 cases in the TCGA AML dataset, we did not 
identify mutations or homozygous deletions in Clock, Bmal1, or Per2 (Figure S5K), 
indicating that key components of the circadian circuitry are intact in AML.
DISCUSSION
Cell non-autonomous roles for the circadian rhythm in hematopoiesis are well established 
(Casanova-Acebes et al., 2013; Lucas et al., 2008; Mendez-Ferrer et al., 2010; Mendez-
Ferrer et al., 2008; Nguyen et al., 2013). Our findings demonstrate a previously 
unrecognized role for the core circadian clock genes in AML. We found that disruption of 
the circadian circuitry, mediated by shRNA knockdown, targeted mutation, or genetic 
deletion of key TFs, impairs the growth of murine leukemia cells in vivo and human cell 
lines in vitro.
We evaluated the cellular mechanisms of leukemia depletion and found that circadian 
perturbation induces myeloid differentiation, including a reduction in cell surface expression 
of c-Kit, a marker of LSCs. Using the Rev-Erb α/β small molecule agonist SR9011, we 
identified a dose-dependent transcriptional down-regulation of HoxA9, Meis1, and Ctnnb1; 
together, these self-renewal TFs cooperate to induce myeloid leukemia in mice and are 
broadly required in multiple AML models (Heidel et al., 2012; Wang et al., 2010). Similarly, 
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in the skin, the circadian clock regulates the expression of stem cell self-renewal genes, 
including those in the Wnt/β-catenin pathway, and loss of Bmal1 results in stem cell 
arrhythmia in squamous cell tumors (Janich et al., 2011). Thus, links between the circadian 
rhythm and self-renewal pathways may be conserved in multiple tissue contexts.
We also found that Clock and Bmal1 regulate cellular proliferation and cell cycle 
progression in AML cells, consistent with phenotypes reported in other systems (Grechez-
Cassiau et al., 2008; Matsuo et al., 2003; Miller et al., 2007). Although some studies indicate 
that specific clock genes may act as tumor suppressors (Fu et al., 2002), other studies 
suggest a more complex relationship between the circadian rhythm and cancer (Antoch et 
al., 2013). Our finding that AML cells require Clock and Bmal1 expression reinforces recent 
work demonstrating tumor-maintaining roles for the core circadian rhythm genes in a variety 
of cancers (Antoch et al., 2008; Cui et al., 2015; Elshazley et al., 2012; Janich et al., 2011; 
Li et al., 2013; Ozturk et al., 2009; Xiao et al., 2014).
Furthermore, targets and binding partners of CLOCK and BMAL1 are relevant to the 
biology and survival of AML cells. A previous study demonstrated that CLOCK and 
BMAL1 form a complex with wild type MLL1, a histone methyltransferase required for 
MLL-AF9 leukemia (Katada and Sassone-Corsi, 2010; Thiel et al., 2010). This association 
results in cyclical H3K4 trimethylation, establishing a permissive chromatin state for 
genome-scale circadian transcription (Koike et al., 2012). If the critical interaction domain 
of MLL1 is preserved in MLL fusions, CLOCK and BMAL1 may physically bind the MLL-
AF9 complex, which includes the H3K79 methyltransferase DOT1L, and target it to 
genomic loci required for leukemia survival (Bernt et al., 2011).
A critical feature of the circadian rhythm is oscillating gene expression in both the SCN as 
well as peripheral tissues. Peripheral circadian rhythms are cell-autonomous and occur in the 
absence of external input (Ko and Takahashi, 2006). Using Per2::Luc knock-in mice, we 
confirmed that MLL-AF9 leukemia cells have the capacity to cycle. Continuous 
bioluminescence recordings of leukemic tissue explants cultured in isolation demonstrated 
persistent oscillations with a period of approximately 24 hours, indicating the presence of an 
intact clock in primary AML cells. Rhythms were maintained with serial transplantation, 
and remarkably, were present in moribund mice with advanced hematologic disease.
Consistent with cyclical gene expression patterns, canonical circadian regulatory 
mechanisms are preserved in leukemia. ChIP-Seq studies demonstrated that the CLOCK/
BMAL1 complex binds to multiple known circadian pathway genes, and binding occurred 
with specificity to E-box regulatory elements (Yu et al., 2006). The MYC/MAX complex 
also has specificity for E-box motifs, indicating that MYC targets may display circadian-
dependent regulation and contribute to cancer phenotypes. In addition, a subset of Clock and 
Bmal1 targets, including Per1 and Cry1, were highlighted in a circadian pathway minipool 
screen as genes required for MLL-AF9 leukemia. Given diverse outputs of the peripheral 
clock in most tissues, it is likely that a set of targets, rather than a single gene, modulates 
LSC function.
Puram et al. Page 9
Cell. Author manuscript; available in PMC 2017 April 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Although rhythmic, circadian-dependent gene expression was present in both normal cells 
and in leukemia, murine genetic knockout studies indicate that Bmal1 is not absolutely 
required for normal hematopoietic function. Interestingly, in the setting of germline loss of 
Bmal1, we observed a reduction in the frequency of LSK cells and LT-HSCs. Despite altered 
stem cell numbers, mature myeloid and lymphoid cells in both the bone marrow and spleen 
were grossly normal and recent work indicates that HSCs from these mice have preserved 
function (Ieyasu et al., 2014). Additionally, we found that selective loss of Bmal1 in adult 
hematopoiesis does not significantly alter HSPC differentiation or multilineage repopulating 
activity in competitive transplantation assays.
In contrast to normal cells, leukemia cells in the MLL-AF9 model depend on Bmal1 
expression. Genetic deletion of Bmal1 in established leukemias results in a competitive 
disadvantage. Leukemia initiation experiments demonstrated that primary leukemias may be 
derived from Bmal1-deficient HSPCs transformed with MLL-AF9. However, serial 
transplantation revealed that loss of Bmal1 increases leukemia latency and impairs disease 
propagation. Consistent with the knockout studies, we found that AML cells, as compared to 
normal HSPCs, are differentially sensitive to circadian perturbation with SR9011.
It remains to be determined if the rhythms of HSCs and LSCs are similar in vivo. 
Differences in these rhythms could be exploited for chronotherapy, in which chemoradiation 
is dosed at a time of day when leukemia cells are selectively sensitive due to cell cycle status 
and/or expression of specific clock output genes. Additionally, drugs that alter the circadian 
rhythm may sensitize leukemia cells to traditional anti-cancer therapies and facilitate 
targeting of cancer stem cells to eliminate disease more effectively.
EXPERIMENTAL PROCEDURES
Mouse Maintenance, Transplants, and Genotyping
All mouse experiments were performed with an IUCAC-approved animal protocol at our 
facility. Specific strains used in this study include C57BL/6J (Jackson Labs), B6.SJL 
(Taconic), Actin-dsRed (006051, Jackson Labs), B6.129S4(Cg)-Arntltm1Weit (007668, 
Jackson Labs), B6.129-Arntltm1Bra (009100, Jackson Labs), B6.129S6-Per2tm1Jt (006852, 
Jackson Labs), and B6.Cg-Per2tm1Brd; Tyrc−Brd/J (003819, Jackson Labs). CD45.1+ cells 
isolated from B6.SJL mice (Taconic) were used for the competitive transplantation studies. 
For all other mouse experiments, C57BL/6J mice (Jackson Labs) were used as controls. 
Prior to tail vein or retro-orbital transplantation, mice were sublethally (1 × 6 Gy [600 rads]) 
or lethally (1 × 9.5 Gy [950 rads]) irradiated as specified. A multiplexed PCR reaction was 
used to genotype Bmal1f/f mice and to assess the efficiency of excision, as described 
previously (Storch et al., 2007). Per2::Luc knock-in mice were genotyped using primers 
oIMR6588, oIMR6589, and oIMR6590 according to Jackson Labs protocols.
All mice used in this study were maintained on a standard LD12:12 schedule. Bone marrow 
and spleen harvests for murine knockout and leukemia studies were generally performed 
between 1 and 5 hours after the initiation of light (Zeitgeber time, ZT1 to ZT5). Control and 
experimental cohorts were always harvested at the same time of day.
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Quaternary Transplant MLL-AF9 Leukemia Model
GMPs were isolated from the bone marrow of Actin-dsRed mice, as described previously 
(Krivtsov et al., 2006). GMPs were spinfected twice (2500 rpm, 90 min, 37° C) with MSCV-
MLL-AF9-Neo retrovirus in SFEM (Stem Cell Technologies) supplemented with murine 
IL3 (mIL3, 10 ng/ml, Peprotech), murine IL6 (mIL6, 10 ng/ml, Peprotech), and murine SCF 
(mSCF, 10 ng/ml, Peprotech), followed by transplantation to lethally irradiated WT 
recipients. After disease onset, leukemic spleen cells were harvested and subsequently 
transplanted to sublethally irradiated secondary recipients. Two additional rounds of 
transplantation resulted in the generation quaternary transplant leukemias with high 
penetrance and short disease latency (Hartwell et al., 2013). Flow cytometry was performed 
using antibodies for the lineage markers CD3, CD4, CD8, B220, CD19, IL7R, and Ter119 
(Caltag), c-Kit (17-1172-83, eBioscience), Sca-1 (11-5981-82, eBioscience), CD34 
(11-0341-85, eBioscience), and CD16/32 (25-0161-82, eBioscience).
Isolation of Leukemia Stem Cells
The long bones and hips of moribund quaternary transplant leukemic mice were harvested, 
cleaned, crushed, and sequentially passed through 100 μM and 70 μM filters (Falcon). 
Following red blood cells lysis (Qiagen), leukemic bone marrow cells were stained with 
APC-conjugated anti-c-Kit (clone 2B8; eBioscience) and Hoechst 33258 (H21491, 
Invitrogen) in PBS with 2% FBS (Omega). LSC-enriched populations were isolated by 
sorting Hoechst−, dsRed+, c-Kithigh (top 10–20 percent) cells (FACS Aria II, Becton 
Dickinson). In the quaternary transplant MLL-AF9 model, the c-Kithigh fraction is 
sufficiently enriched for leukemia-initiating cells, as described previously (Hartwell et al., 
2013; Miller et al., 2013). Quaternary transplant leukemia cells were used for experiments 
presented in Figures 1A–G, 2B–H, and 5C.
ChIP-Seq
ChIP-Seq was performed as previously described (Kowalczyk et al., 2012) with minor 
modifications. Specifically, THP-1 cells were fixed in 2 mM EGS (Thermo Scientific) for 30 
or 60 minutes followed by 1% formaldehyde for 30 or 15 minutes at RT, respectively. 
Chromatin was sonicated to a size less than 500 bp and then incubated overnight with either 
anti-Clock IgG (ab3517, Abcam) or anti-Bmal1 IgG (ab3350, Abcam). ChIP-Seq libraries 
were prepared through the process of DNA end-repair (Epicentre), A-base addition, and 
adaptor ligation using indexed Illumina adaptors followed by enrichment PCR. All 
enzymatic steps were carried out using enzymes from New England Biolabs. Final libraries 
were pooled, size selected, and sequenced on HiSeq2500 with 25 paired-end reads.
ChIP-Seq Data Analysis
Paired-end reads for both ChIP and input samples were mapped to the hg19 version of the 
human genome using Bowtie 2 (Langmead and Salzberg, 2012), only keeping read pairs that 
map uniquely to the genome. Peaks were called using findPeaks from the Homer suite 
(v4.7.2) (Heinz et al., 2010) with “-style factor -fdr 0.01 -LP 0.01 -P 0.1” parameters and 
using input data as background. The intersection of peaks for CLOCK and BMAL1 was 
used to define a high-confidence set of binding sites. Identification of target genes associated 
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with these binding sites and functional enrichment analysis were completed using GREAT 
(v2.0.2) (McLean et al., 2010). H3K4me3 peaks (SRA accession ERS148524) were set as 
background to control for activity/inactivity of genes. We identified 269 peaks associated 
with 406 genes for CLOCK and 9584 peaks associated with 8027 genes for BMAL1. 
Focusing on the intersection of CLOCK and BMAL1 peaks, we identified 140 binding sites 
associated with 229 genes. Motif analysis of high-confidence sites was performed using 
RSAT peak-motifs (Thomas-Chollier et al., 2012). Gene ontology analysis (Ashburner et al., 
2000) was completed using the GO Slim web portal (http://go.princeton.edu). ChIP-Seq data 
presented in this study may be accessed on Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) with GEO ID GSE70686.
Statistics
Kaplan Meyer analysis (Mantel-Cox test) and EC50 calculations were completed using 
GraphPad Prism 6. Statistical analysis was completed using R (www.r-project.org) or Excel 
(Microsoft) software. Mean values are shown (unless otherwise specified) and error bars 
represent standard error of the means. Flow cytometry gating and MFI analysis were 
completed using FlowJo 7.6.1 software. Statistical significance was determined using a two-
sided Student’s t-test (*p<0.05, **p<0.01, ***p<0.001).
Detailed descriptions of additional experimental and analytical methods are included in the 
Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clock and Bmal1 are required for leukemia cell growth
(A) Pooled RNAi screen identified shRNAs depleting murine MLL-AF9 leukemia cells in 
vivo. Heat map depicting the log2 transformed representation of individual shRNAs (rows) 
in the input replicates (n=5, left columns) and leukemic bone marrow replicates (n=5, right 
columns). Depleted shRNAs are shown in blue. (B) Performance of shRNAs targeting 
negative control genes (black), positive control genes (red), and circadian rhythm genes 
(blue). Plots depict the log10 median fold change for each shRNA. Fraction of shRNAs with 
fold depletion > 20 is shown. (C–D) Fold change in the percentage of GFP+ murine MLL-
AF9 leukemia cells transduced with single Clock (C2, C6, C12) (n=3), Bmal1 (A1, A6, 
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A11) (n=3), or Luc (n=3) shRNAs co-expressed with GFP (C) in vivo or (D) in vitro. (E) 
Phenotypic rescue of Bmal1 knockdown with an shRNA-resistant Bmal1 cDNA in murine 
MLL-AF9 leukemia cells. (F) In vitro tracking of Cas9-expressing murine MLL-AF9 
leukemia cells transduced with sgRNAs targeting Bmal1 (sgBmal) (n=3), HoxA9 
(sgHoxA9) (n=3), or Luc (sgLuc) (n=3) co-expressed with RFP657. (G) Detection of in-
frame and out-of-frame mutations at the Bmal1 locus in cells expressing Cas9 and sgBmal1 
by Sanger sequencing of individual clones. *p<0.05, **p<0.01, ***p<0.001, determined by 
a two-sided Student’s t-test. Mean values are shown unless otherwise specified, and error 
bars represent +/− S.E.M.
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Figure 2. Disruption of the circadian rhythm machinery induces leukemia differentiation
(A) RNA-Seq analysis of Bmal1 expression in c-Kithigh (top 10 percent, n=3) and c-Kitlow 
(bottom 10 percent, n=3) leukemic bone marrow cells from primary, secondary, tertiary, and 
quaternary transplant MLL-AF9 mice. TPM, transcripts per million. (B) Dose response 
curve showing relative viability (y-axis) of murine MLL-AF9 leukemia cells treated for 3 
days with varying concentrations of SR9011 (x-axis, log scale) (n=3). (C–D) Expression of 
(C) circadian rhythm genes (Bmal1, Per2) or (D) regulators of LSC self-renewal (HoxA9, 
Meis1, Ctnnb1), measured by quantitative RT-PCR following treatment of murine MLL-AF9 
leukemia cells with 3.125 μM SR9011 (n=4), 6.25 μM SR9011 (n=4), or DMSO (n=4) for 
24 hours. (E) Wright-Giemsa staining of murine MLL-AF9 leukemia cells transduced with 
single Clock (C2, C12) or Bmal1 (A1, A6) shRNAs revealed monocytic differentiation 
(black arrows). (F) Representative flow cytometry histograms of c-Kit cell surface 
expression (x-axis, log scale) in GFP+ murine MLL-AF9 leukemia cells expressing Clock 
(C2, C12), Bmal1 (A1, A6), or Luc shRNAs. (G) Quantification of c-Kit cell surface 
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expression by median fluorescence intensity (MFI) analysis. (H) Hoechst33342 cell cycle 
analysis of murine MLL-AF9 leukemia cells transduced with Clock (C2, n=3), Bmal1 (A1, 
n=3), or Luc (n=3) shRNAs. Data for both transduced (GFP+) and untransduced (GFP−) 
cells within the same replicate are shown. *p<0.05, **p<0.01, ***p<0.001, determined by a 
two-sided Student’s t-test. Mean values are shown unless otherwise specified, and error bars 
represent +/− S.E.M.
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Figure 3. Canonical circadian regulatory mechanisms are intact in primary murine leukemia 
and human AML
(A) Continuous bioluminescence recording of a leukemic spleen explant from a WT 
secondary recipient mouse transplanted with Per2::Luc MLL-AF9 leukemia cells. (B) Cell 
titer glo assay showing viability of SKM-1 or THP-1 cells following transduction with 
shRNAs targeting CLOCK (D10, D12) (n=5), BMAL1 (F4, F5) (n=5), or LUC (n=5). Equal 
numbers of puromycin-selected cells were plated 3 days after transduction and followed for 
2 weeks in vitro. Data is normalized to the shLUC control at each timepoint. (C) CLOCK 
and BMAL1 reciprocal co-immunoprecipitation in THP-1 cells. (D) UCSC genome browser 
tracks of CLOCK (red) and BMAL1 (black) occupancy at the CRY1, NR1D1, PER1, and 
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DBP loci in THP-1 cells based on normalized ChIP-Seq read coverage. Track heights are 
indicated. (E) Gene ontology analysis of pathways represented by high-confidence CLOCK/
BMAL1 targets. Pathways of interest are highlighted in red. (F) RSEM motif enrichment 
analysis of high-confidence regions identified in CLOCK and BMAL1 ChIP-seq. (G) 
Minipool shRNA screen of 22 canonical circadian regulators in murine MLL-AF9 leukemia 
cells. Hits from the screen are shown in red and high-confidence Clock/Bmal1 ChIP-Seq 
targets are marked with a black arrow. Mean values are shown unless otherwise specified, 
and error bars represent +/− S.E.M.
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Figure 4. Bmal1 is dispensable for normal HSC function
(A–B) Continuous bioluminescence recording of spleen explant from (A) homozygous 
Per2::Luc transgenic mouse or (B) lethally irradiated WT mouse transplanted with c-Kit 
enriched Per2::Luc bone marrow. (C–D) Expression of (C) Clock or (D) Bmal1 in murine 
LSK cells (n=3), LK cells (n=3), and lineage+ cells (n=3) purified from wild type mice, as 
measured by qPCR. (E) Representative flow cytometry contour plots of LSK cells in the 
bone marrow of germline Bmal1−/− and Bmal1+/− mice. LSK frequency is presented as a 
percentage of viable whole bone marrow. (F–I) Quantification of (F) LSK cells, (G) LT-
HSCs, (H) lineage+ cells, and (I) myeloid progenitor cells in the bone marrow of germline 
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Bmal1−/− (n=6) and Bmal1+/− (n=6) mice. Data is presented as a percentage of viable whole 
bone marrow. (J) Peripheral blood CD45.2 chimerism in Bmal1+/+; MxCre+ (n=7) and 
Bmal1f/f; MxCre+ (n=6) competitive transplant mice following poly(I:C) treatment. (K–L) 
CD45.2 chimerism in the bone marrow LSK and LT-HSC compartments of Bmal1+/+; 
MxCre+ and Bmal1f/f; MxCre+ (K) primary or (L) secondary competitive transplant mice. 
*p<0.05, **p<0.01, ***p<0.001, determined by a two-sided Student’s t-test. Mean values 
are shown unless otherwise specified, and error bars represent +/− S.E.M.
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Figure 5. Genetic knockout models reveal a leukemia-specific dependence on Bmal1
(A) Top panel shows genotyping of Bmal1f/f and Bmal1+/+ MLL-AF9 leukemias before and 
after transduction with PIG-Cre. Dotted white line indicates spliced gel. Bottom panel shows 
normalized cell counts of Bmal1f/f (n=4) and Bmal1+/+ (n=4) MLL-AF9 leukemias 
transduced with PIG-Cre in vitro. Puromycin-selected cells were plated 84 hours after 
transduction and followed over time. (B) Bmal1f/f; MxCre+ mice and Bmal1+/+; MxCre+ 
controls were treated with poly(I:C) to induce hematopoietic-specific Cre expression. Bone 
marrow cells harvested from these mice were c-Kit enriched, transduced with MIG-MLL-
AF9, and transplanted to lethally irradiated WT recipient mice. The resulting Bmal1−/− or 
Bmal1+/+ MLL-AF9 leukemias were transplanted to sublethally irradiated secondary 
recipients. Kaplan-Meier survival curves for the primary and secondary transplants are 
shown. (C) Normalized cell counts of quaternary transplant MLL-AF9 cells (n=3) and 
murine LSK cells (n=3) following treatment with DMSO or SR9011 for 3 days in vitro. (D) 
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Cell titer glo assay showing normalized viability of NOMO-1 (n=3), MOLM-13 (n=3), and 
CD34+ cord blood cells (n=6) following treatment with DMSO or SR9011 for 4 days in 
vitro. *p<0.05, **p<0.01, ***p<0.001, determined by a two-sided Student’s t-test. Mean 
values are shown unless otherwise specified, and error bars represent +/− S.E.M.
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